These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Eradication of HIV: the cutting edge of clinical trial design.
    Journal: Crit Path AIDS Proj; 1996; (No 31):16-7. PubMed ID: 11363825.
    Abstract:
    The AIDS Clinical Trials Group (ACTG) will begin in October 1996, a new clinical trial that will compare three long-term maintenance regimens. Recruits in the randomized double-blind study, ACTG 343, will receive induction therapy with AZT, 3TC, and indinavir (Crixivan; IDV), the Merck protease inhibitor. Volunteers with an undetectable HIV RNA after 6 months will be randomized to one of three maintenance regimens: AZT/3TC vs. IDV alone vs. continuing on AZT/3TC/IDV. Treatment will be withdrawn from subjects with undetectable HIV RNA at 6-month intervals, after the initial 6-month maintenance therapy. If any virus is detected, the combination of AZT/3TC/IDV will be resumed. The investigators hope to compare the proportion of patients who sustain suppression of HIV RNA among the three regimens during the maintenance phase and after therapy is withdrawn.
    [Abstract] [Full Text] [Related] [New Search]